Li-Hao Chu
Kaiser Permanente
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Li-Hao Chu.
Alimentary Pharmacology & Therapeutics | 2012
George F. Longstreth; Rajan L. Iyer; Li-Hao Chu; Wansu Chen; Linnette Yen; Paul Hodgkins; Aniket A. Kawatkar
Computed tomography (CT) demonstrates diverticulitis severity.
Arthritis Care and Research | 2013
Li-Hao Chu; Cecilia Portugal; Aniket A. Kawatkar; William Stohl; Michael B. Nichol
To assess racial/ethnic differences in the use of biologic disease‐modifying antirheumatic drugs (DMARDs) among California Medicaid (Medi‐Cal) rheumatoid arthritis (RA) patients.
Arthritis Care and Research | 2014
Ivett Garcia; Cecilia Portugal; Li-Hao Chu; Aniket A. Kawatkar
To compare survey response rates and preferences for 3 modes of survey administration in rheumatoid arthritis (RA) patients.
Current Medical Research and Opinion | 2014
Tara K. Knight; Aniket A. Kawatkar; Paul Hodgkins; Robert Moss; Li-Hao Chu; Vanja Sikirica; M. Haim Erder; Michael B. Nichol
Abstract Objectives: To estimate longitudinal trends in prevalence and incidence rates of adult ADHD 2006–2009. Research design and methods: Kaiser Permanente Southern California (KPSC) electronic medical records were analyzed to assess prevalence and incidence rates for adult ADHD. Trends over time were estimated and compared using three case definitions (ADHD diagnosis only [DX], ADHD DX and ≥2 FDA-approved ADHD prescriptions [DX + RX], and ADHD DX and ≥1 behavioral therapy visit [DX + BT]). Main outcome measures: Prevalence and incidence rates of adult ADHD. Results: Prevalence ranged from 151 (DX + RX) to 312 (DX) cases per 100,000 members in 2006, increasing to 239 (DX + RX) and 415 (DX) cases in 2009. Prevalence based on DX + BT declined from 185 in 2006 to 94 cases per 100,000 in 2009. In 2006, incidence ranged from 15 (DX + BT) to 68 (DX) cases per 100,000 person-years. Incidence rates remained stable throughout the study period. Stratified analyses based on DX + RX revealed only slight variations by gender, but sharp differences by age, with younger adults demonstrating a higher prevalence overall as well as dramatic increases over the study period. Prevalence was highest among Caucasians, increasing substantially across all race groups over time. Limitations: A limitation of this study is that incidence rates may not be representative of new cases if diagnoses existed prior to enrollment in KPSC. Similarly, prevalence rates may be affected if patients sought care outside of the health plan. Conclusions: Adult ADHD prevalence in this managed care organization appears low, but showed increasing prevalence and incidence rates over time.
Pharmacoepidemiology and Drug Safety | 2015
Aniket A. Kawatkar; Li-Hao Chu; Rajan L. Iyer; Linnette Yen; Wansu Chen; M. Haim Erder; Paul Hodgkins; George F. Longstreth
The objectives of this study were to develop and validate algorithms to accurately identify patients with diverticulitis using electronic medical records (EMRs).
Value in Health | 2014
Aniket A. Kawatkar; Tara K. Knight; Robert Moss; Vanja Sikirica; Li-Hao Chu; Paul Hodgkins; M. Haim Erder; Michael B. Nichol
OBJECTIVE To estimate the health resource use (HRU) and expenditure of adult patients with attention deficit/hyperactivity disorder (ADHD) subsequently diagnosed with one or more mental health (MH) comorbidities. METHODS Using Kaiser Permanente Southern California electronic medical records (January 1, 2006, to December 31, 2009), we identified adults with at least one ADHD diagnosis and at least two subsequent prescriptions fills for ADHD medication. The date of first MH comorbidity diagnosis after the index ADHD diagnosis was defined as the index transition date. Continuous eligibility 12 months before and after the index transition date was required. For patients with multiple transitions (≥2), the post-transition period reflected the 12 months after the second transition. HRU for all-cause inpatient, outpatient, emergency department, behavioral therapy, overall prescription fill counts, and ADHD-specific prescription fill counts and mean patient expenditure (2010 US
Value in Health | 2012
Li-Hao Chu; A.A. Kawatakar
) were estimated. Generalized estimating equations were used to evaluate differences in HRU and expenditure between the pre- and post-transition periods, respectively. RESULTS Of the 3809 patients with ADHD identified, 989 (26%) had at least one transition (n = 357 single and n = 632 multiple). From the pre- to the post-transition period, for single transition cohort, all HRU increased significantly except for behavioral therapy. In the multiple transition cohort, all HRU increased significantly. Total expenditure increased by mean ± SE of
Archive | 2014
Tara K. Knight; Aniket A. Kawatkar; Paul Hodgkins; Robert Moss; Li-Hao Chu
1822 ±
Value in Health | 2012
Aniket A. Kawatkar; Li-Hao Chu; W. Chen; Linnette Yen; M.H. Erder; Paul Hodgkins; R. Iyer; George F. Longstreth
306 and
Gastroenterology | 2012
Aniket A. Kawatkar; George F. Longstreth; Linnette Yen; Li-Hao Chu; Wansu Chen; Paul Hodgkins; Moshe H. Erder; Rajan L. Iyer; Michael B. Nichol
4432 ±